From The Economic Times · Rica Bhattacharyya · · 1m 10s
Bharat Biotech Returns to Innovation After Pandemic
Bharat Biotech founder Krishna Ella reveals post-Covid reset, TB vaccine progress, and future focus on Africa.
In brief
Bharat Biotech founder Krishna Ella reveals post-Covid reset, TB vaccine progress, and future focus on Africa. Bharat Biotech aims to make gene therapy affordable for India's middle class and target African health needs. Originally reported by The Economic Times.
Post-Covid Reset
Bharat Biotech founder Krishna Ella says the company took two years to reset after pandemic work.
“Momentum fizzled out a little bit. Employees also lost energy after working so hard in the Covid time.”
TB Vaccine Progress
The TB vaccine has completed phase 2 trials and is submitting phase 3 data for review.
“Phase 2 is completed. Submitting the dossier; it has been reviewed already.”
Gene Therapy Focus
Bharat Biotech aims to make gene therapy affordable for India's middle class through Bengaluru facility.
“Today the therapy costs Rs 1-3 crore or even more. Our aim is to make it affordable.”
Nipah and Ebola Vaccines
Krishna Ella is developing Nipah and Ebola vaccines with a focus on T-cell-based approaches for pandemic preparedness.
“I am now focusing on two pandemic vaccines from the point of view of preparedness. One is a Nipah vaccine and the second is Ebola.”
IPO Plans
Bharat Biotech is exploring IPO options to fund new therapies and de-risk investments.
“I am not denying it. But definitely when I want to go to new therapies like monoclonal antibodies, I need some money to push the game.”
Next Generation
Krishna Ella's children are leading human vaccines and gene therapy efforts, with daughter focusing on veterinary science.
“My son (Raches Ella) is looking after the human vaccines and gene therapy. My daughter (Jalachari Ella) is on the veterinary side.”
Africa Focus
Bharat Biotech aims to become a major public health contributor for Africa through vaccines and veterinary programs.
“I want to help the African continent with human vaccines, veterinary, and agriculture.”
Financial Strategy
Bharat Biotech has Rs 2,000 crore revenue, is debt-free, and invested Rs 1,500 crore in Odisha manufacturing.
“We are around Rs 2,000 crore revenue now. But we are stabilised. We are a debt-free company.”
What matters most
Bharat Biotech aims to make gene therapy affordable for India's middle class and target African health needs.
